Comments
Transgene Biotek Ltd, today announced the sale of technology for recombinant human Erythropoietin (rh-EPO) to TSS EXPORT GmbH FZE, one of the group companies of the TSS Group for $5 million.
The technology transfer and sale is expected to be completed within 6 months.
Transgene had earlier out-licensed two of its technologies -- a recombinant Hepatitis B vaccine to one of the largest vaccine producers in the world and more recently Orlistat to one of the Indian pharma companies with a significant presence in the global arena.
Dr K.K. Rao, Managing Director, Transgene Biotek, in a statement said, “this transaction fulfils the pledge to focus on revenue generation and monetising the sale of underutilised bio-generic drug assets; those developed by the company during the last 7-8 years but which we now feel do not fit into our new agenda for sustained growth.”
The company recently started commercial manufacture of DHA, an Omega-3 Fatty acid used in the nutraceuticals and health supplements market. While manufacturing from leased facilities, Transgene is in the process of expanding its own in-house infrastructure to augment production capacities for this and other APIs (active pharma ingredients) coming into production. Transgene also expects to begin commercial manufacturing of a second API called Tacrolimus shortly.
The company management is in talks with manufacturers in Europe and North America for strategic partnerships to manufacture and distribute these products to regulated markets.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.